ERLYSIGN Kit
Pre-clinical- Indications
- Oral cancer
Company intelligence / Profile preview
CURO Biosciences has developed a non-invasive saliva-based test kit ("ErlySign") that diagnoses oral precancerous conditions within 15 minutes. Initial studies report 100% specificity and 98.04% sensitivity. The product is in advanced clinical trials at multiple hospital sites in India. The company recently secured ₹16 crore (~$2M) in pre-Series A funding to support regulatory approval and commercialization efforts. They are also developing a CRISPR miRNA platform to enable rapid multi-cancer detection from saliva samples
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CURO Biosciences Pvt Ltd.